This program seeks to enhance the health and well-being of the citizens of Taiwan and the world, transform Taiwan into an Asia-Pacific biomedical R&D hub, boost biotech industry through the establishment of an effective industry ecosystem, and promote the development of innovation clusters, collaboration with international markets, and the growth of distinctive industries.
The government's strategy for the biotech medicine industry under the "5+2 Industrial R&D Program" will be implemented with a chief focus on "innovation, employment, and distribution" in accordance with the blueprint drafted by President Tsai’s cabinet. The program will primarily allocate resources to five innovation-centered industries that promise to improve the long-term growth of the local economy. MOST is aggressively implementing this program in collaboration with other agencies, including the Ministry of Economic Affairs, Ministry of Health and Welfare, and the National Development Council. Chief action plans are as follows:
1. Creation of a biomedical corridor: The program will integrate Taiwan's existing innovation clusters in the form of a single biomedical corridor stretching the length of the island and including all facets of the biomedical value chain.
2. Upgrading infrastructure and ecosystem: The program will enhance the efficiency of innovation by building a basic infrastructure and upgrading the biomedical research, development, investment, and marketing ecosystem. The program will also improve and clarify laws and regulations, train talent, and promote raising of capital in order to create a friendly environment for accelerated growth.
3. Connecting with the world: The program will engage with international markets, establish relationship with global research institutes, recruit international elite personnel, and build innovative R&D centers.
4. Paving the way for the industry’s future: The program will promote major industries and specific areas, including welfare for an aging population, precision medicine, and specialty biomedical solutions. In addition, the program will address new technologies and therapies, including digital health, artificial intelligence, and cell therapy.